Sansheng Guojian is only one step away from the meeting

On November 25, according to the development of science and Technology Innovation Board of Shanghai Stock Exchange, Sansheng Guojian entered the stage of inquiry, indicating that the information of Sansheng Guojian has passed the examination of science and technology innovation board, and the next step will be to submit it to the meeting of Shanghai Municipal Committee for examination The official website of science and Technology Innovation Board of Shanghai stock exchange accepted the listing application of Sansheng Guojian on October 31 The company plans to raise 3.183 billion yuan in science and technology innovation board, which is exclusively sponsored by Huatai United Securities According to the prospectus, Sansheng Guojian is in line with the listing standard specified in Item (4) of article 2.1.2 of Listing Rules of science and Technology Innovation Board of Shanghai Stock Exchange: the estimated market value is not less than 3 billion yuan, and the operating revenue in the latest year is not less than 300 million yuan Sansheng Guojian is the only enterprise in China that has two therapeutic antibody drugs on the market at present, which are recombinant human type II tumor necrosis factor receptor antibody fusion protein (yisaipu) and recombinant anti-CD25 humanized monoclonal antibody injection (genipiper) Yisaipu is the first all human antibody drug listed in China, the first all human antibody drug listed in China's rheumatic field, and the first biological preparation listed in China's rheumatic field Genipipex was marketed in October 2019 to prevent acute rejection caused by renal transplantation It can be used in combination with conventional immunosuppression programs to significantly improve the survival rate of transplanted organs and the quality of life of patients In addition, the company has 15 main antibody products under development ① Products under development in clinical and post stage ② Products under development in preclinical stage